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Abstract 
The Notch pathway is highly active in almost all patients with T-cell acute lymphoblastic leukemia (T-ALL), but 
the implication of Notch ligands in T-ALL remains underexplored. 
Methods: We used a genetic mouse model of Notch ligand delta like 4 (DLL4)-driven T-ALL and performed 
thymectomies and splenectomies in those animals. We also used several patient-derived T-ALL (PDTALL) 
models, including one with DLL4 expression on the membrane and we treated PDTALL cells in vitro and in vivo 
with demcizumab, a blocking antibody against human DLL4 currently being tested in clinical trials in patients 
with solid cancer. 
Results: We show that surgical removal of the spleen abrogated T-ALL development in our preclinical 
DLL4-driven T-ALL mouse model. Mechanistically, we found that the spleen, and not the thymus, promoted 
the accumulation of circulating CD4+CD8+ T cells before T-ALL onset, suggesting that DLL4-driven T-ALL 
derives from these cells. Then, we identified a small subset of T-ALL patients showing higher levels of DLL4 
expression. Moreover, in mice xenografted with a DLL4-positive PDTALL model, treatment with demcizumab 
had the same therapeutic effect as global Notch pathway inhibition using the potent γ-secretase inhibitor 
dibenzazepine. This result demonstrates that, in this PDTALL model, Notch pathway activity depends on DLL4 
signaling, thus validating our preclinical mouse model. 
Conclusion: DLL4 expression in human leukemic cells can be a source of Notch activity in T-ALL, and the 
spleen plays a major role in a genetic mouse model of DLL4-driven T-ALL. 










The Notch pathway plays a major role in T-cell 
acute lymphoblastic leukemia (T-ALL). Indeed, more 
than 60% of patients harbor NOTCH1 activating 
mutations and between 8 and 30% have inactivating 
mutations in FBXW7, a NOTCH1 negative regulator 
[1]. In solid tumors, activating mutations in the Notch 
pathway are less frequent, but overexpression of 
Notch ligands in cancer cells has been reported as a 
mechanism to increase Notch pathway activity, for 
instance in breast and lung cancer [2, 3]. However, to 
the best of our knowledge, Notch ligand expression 
has never been observed in patients with T-ALL, and 
their clinical relevance remains limited to seminal 
works that identified stromal Notch ligand delta like 4 
(DLL4) as a source of Notch pathway hyperactivation 
in T-ALL [4, 5]. 
Conversely, using preclinical mouse models, we 
and others demonstrated that ectopic DLL4 
expression in hematopoietic stem cells (HSCs) or T 
cells leads to spontaneous T-ALL development [6, 7] 
that is preceded by accumulation of non-clonal 
double-positive CD4+CD8+ cells in the circulation [6, 
7]. However, the tissue of origin of these peripheral 
CD4+CD8+ cells and their role in T-ALL were not 
known. Therefore, here, we used Tg8 mice, a genetic 
mouse model of T-ALL induced by DLL4 ectopic 
expression in T cells [6], and found that the spleen 
was the major peripheral lymphoid organ for 
extrathymic T cell development, with enrichment of 
all CD4+CD8+ cell precursors. Splenectomy inhibited 
peripheral CD4+CD8+ cell accumulation. Moreover, 
splenectomy, but not thymectomy inhibited 
DLL4-driven T-ALL development, suggesting that 
circulating CD4+CD8+ cells are at the origin of T-ALL 
in this mouse model. 
Then, to determine the role of human DLL4 in 
T-ALL, we first analyzed DLL4 mRNA expression in 
T-ALL samples and found high DLL4 expression in a 
subset of these specimens. Moreover, in a small 
collection of patient-derived T-ALL xenografts 
(PDTALL), we identified one in which DLL4 was 
expressed at the cell membrane. In this PDTALL, 
exposure to demcizumab, a blocking antibody against 
human DLL4 tested in clinical trials in patients with 
solid cancer [8, 9], had similar effects as global Notch 
pathway inhibition using the potent γ-secretase 
inhibitor dibenzazepine (DBZ). This demonstrated 
that in this PDTALL model, Notch pathway activity 
depends on DLL4 expression on T-ALL cells. 
In summary, we demonstrated that spleen is 
crucial for DLL4-driven T-ALL generation in the Tg8 
mouse model, and that DLL4 expression on T-ALL 
cells promotes Notch activity in human T-ALL, 
validating our preclinical findings. 
Results 
In Tg8 mice, circulating CD4+CD8+ cells are 
not exported from the thymus, but from the 
spleen 
Previous studies showed that in different mouse 
models of DLL4-driven T-ALL, non-tumoral 
circulating CD4+CD8+ cells appear before disease 
onset [6, 7]. However, the source of these CD4+CD8+ 
cells and their role in T-ALL are unknown. Therefore, 
we characterized their appearance in Tg8 mice. 
In newborn Tg8 mice, we did not detect any 
CD4+CD8+ cell outside the thymus (Figure 1A). 
Conversely, in 3-week-old mice, we observed 
CD4+CD8+ cells in the spleen, and to a lower extent 
also in other organs: mesenteric and inguinal lymph 
nodes (mLN and ILN), bone marrow (BM), and liver. 
In 7-week-old mice, CD4+CD8+ cells were the most 
abundant lymphoid cell population in spleen, 
suggesting that spleen is the main organ in which 
such cells accumulate outside the thymus in Tg8 mice. 
Next, to determine whether these peripheral 
CD4+CD8+ cells originated in the thymus, we injected 
biotin in the thymus of 5-week-old wild type (WT) 
and Tg8 mice. Biotin uniformly labeled thymocyte 
populations (CD4+CD8+, and CD4+ or CD8+ single- 
positive cells) (Figure S1A). At 24 h post-injection, we 
observed biotin+/CD4+ and biotin+/CD8+ cells in 
spleen and mLN in both genotypes. Conversely, 
double-positive CD4+CD8+ cells in spleen and mLN 
were not labeled by biotin (Figure 1B-S1B), suggesting 
that they were not exported from the thymus or were 
exported much more slowly than mature T cells. 
As spleen was the first peripheral organ showing 
CD4+CD8+ cells, we hypothesized that they could be 
generated in this organ. Therefore, we injected biotin 
in the spleen of WT and Tg8 mice, and 24h later we 
tracked biotin+ cells. We found biotin+/CD4+CD8+ 
cells in most of the organs examined, except thymus 
(Figure 1C), indicating that, unlike thymic CD4+CD8+ 
cells, splenic CD4+CD8+ cells can rapidly circulate to 
other peripheral organs. As most splenic CD4+ and 
CD8+ single-positive cells belonged to the 
recirculating pool of mature T cells, we found biotin+/ 
CD4+ and biotin+/CD8+ single-positive cells in both 
WT and Tg8 peripheral organs after intrasplenic 
biotin injection (Figure 1C-S1C). 
To confirm these results, we transferred a 
mixture of CD4+CD8+ double-positive and CD4+ 
single-positive T cells from donor Tg8 spleens to the 
spleen or thymus of recipient Tg8 mice. We could 
distinguish the three cell types (donor CD4+CD8+, 
donor single-positive, and recipient T cells) using 
Thy1 allelic markers (Figure S2A). Analysis of the 
distribution of the injected cells after 3 days showed 





that both CD4+CD8+ and CD4+ cells injected in the 
spleen migrated to mLN (Figure S2B red square and 
S2C). Conversely, only CD4+ single-positive cells, but 
not CD4+CD8+ cells injected in the thymus migrated 
to mLN (Figure S2B, blue square and S2C). Analysis 
in CD4+CD8+ cells (from the spleen or thymus), as 
well as in CD4+ single-positive cells, showed that both 
splenic and thymic CD4+CD8+ cells weakly expressed 
CCR7 and CD62L compared with mature CD4+ cells 
(Figure S2D). These markers are needed in mature 
single-positive T cells to egress the thymus and 
migrate into LN [10, 11]. 
Altogether, these findings indicated that in Tg8 




Figure 1. Circulating CD4+CD8+ cells in Tg8 mice are not exported from the thymus but from the spleen. A) Kinetics of CD4+CD8+ cell appearance in thymus, 
spleen, mesenteric lymph nodes (mLN), inguinal lymph nodes (ILN), bone marrow (BM), and liver of Tg8 mice determined by flow cytometry (data are representative of n = 4 
mice for each indicated time point). Cells were positively gated using CD3 and analyzed for the expression of CD4 and CD8. B) Biotin was injected into the thymus of 5-week-old 
Tg8 or wild type (WT) mice. 24 h later, biotin+ cells recently emigrated from the thymus were identified in spleen and mLN by staining with an anti-biotin antibody. Data are the 
mean ± SEM (n = 4 mice per genotype). C) Biotin was injected in the spleen of 5-week-old Tg8 or WT mice. 24 h later, biotin+ cells recently emigrated from the spleen were 
identified in thymus, mesenteric lymph nodes (mLN), inguinal lymph nodes (ILN), bone marrow (BM), and liver. Data are the mean ± SEM (n = 3 mice per genotype). In (B) and 
(C) cells were gated using CD3 and analyzed for streptavidin and CD4 and CD8 expression. In (B) and (C): * p < 0.05 ** p < 0.01 (Mann–Whitney test). DP, CD4+CD8+ 
double-positive cells; 4SP, CD4+ single-positive cells; 8SP, CD8+ single-positive cells; w.o., week-old. 





All early T-cell developmental stages are found 
in the spleen 
The findings on peripheral CD4+CD8+ cell 
accumulation and export kinetics suggested that 
spleen could be a preferential site of extrathymic 
CD4+CD8+ T-cell generation in Tg8 mice. Therefore, 
we investigated the presence of double-negative cells 
(i.e. CD4+CD8+ progenitors) during T-cell 
development. Analysis of CD44 and CD25 expression 
in the CD3/4/8/19/11c/F4/80/Gr1/FcεRI/TCRγδ 
(LIN)-negative/Thy1-positive population indicated 
that all double-negative precursors (DN1 to 4) were 
present in spleens of Tg8 mice, but not of WT animals 
(Figure 2A). We did not detect any double-negative 
cell in BM or liver (Figure 2A), indicating that spleen 
might favor DLL4-driven T-cell development in vivo 
outside the thymus in Tg8 mice. Moreover, in Tg8 
mice, DN2 and DN3 spleen cells expressed pre-TCRα, 
confirming their identity as double-negative T cells 
(Figure 2B). 
Next, we wanted to identify the multipotent 
hematopoietic progenitors that could give rise to 
double-negative cells in the spleen of Tg8 mice. Flow 
cytometry analysis showed that in 3-week-old Tg8 
mice, spleen already contained a population of cells 
with multipotent progenitor markers (LSK cells: LIN-, 
Sca1+, cKit (i.e., CD117)+ cells (Figure 2C). The number 
of LSK cells was 5 times lower in spleens from WT 
animals than from Tg8 mice (Figure 2C), indicating 
that LSK cells accumulated better in Tg8 spleens. As 
expected, the percentage of LSK cells was higher in 
BM than in spleen; however, unlike spleen, the 
proportion of LSK cells in BM was similar in Tg8 and 
WT mice (Figure 2C). 
We next assessed whether in Tg8 mice, spleen 
could support development of WT T cells. To this aim, 
we injected WT BM cells in the spleen of Tg8 and WT 
mice. At day 10 post-injection, we detected donor WT 
CD4+CD8+ cells only in the spleen of Tg8 mice, but not 
of WT animals (Figure S2E). 
All these results are in accordance with our 
seminal study showing that transfer of Tg8, but not 
WT single-positive CD4+ cells can promote CD4+CD8+ 
cell development in nude mice [6]. 
LSK cells accumulate in the bridging channels 
of splenic white pulp 
To better characterize the early events of 
CD4+CD8+ cell generation in spleen, we analyzed by 
immunofluorescence the spleen of 14-day-old Tg8 
and WT mice. In Tg8 spleens, CD4+CD8+ cell 
accumulation started immediately adjacent to 
bridging channels (BC), which are identified by the 
presence of marginal sinus-lining MADCAM1+ 
endothelial cells (Figure 2D). This is exactly the site 
where circulating T cells enter the spleen white pulp 
[12]. LSK cells (identified as cKit+ FcεRI-) also were 
near the BC in Tg8 spleens (Figure 2E). This suggests 
that in Tg8 spleens, BCs might provide the proper 
environment for the contact between LSK cells and 
DLL4+ positive T cells to initiate their differentiation 
along the T-cell lineage. In Tg8 spleens, we did not 
detect any LSK cell outside the BC area, including the 
red pulp. Moreover, we did not detect LSK cells in WT 
spleens by immunofluorescence (Figure 2E). Together 
with the flow cytometry analysis (Figure 2C), this 
indicated that the WT spleen environment does not 
favor the accumulation of circulating LSK cells. 
CD4+CD8+ cell number strongly increased in 
35-day-old Tg8 mice (Figure S3A). 
One simple explanation for T-cell development 
in spleen could be its very high density of T cells 
(hence, more DLL4 ligands) compared with other 
lymphoid organs. As T-cell density in LN is at least as 
high as in spleen, we compared the location/density 
of CD4+CD8+cells in mLN and spleen in 7-week-old 
mice, because at this age mLN was the second organ 
after spleen to harbor CD4+CD8+ cells (Figure 1A). 
The density of single-positive cells (hence, DLL4 
density) in mLN was at least as high (if not more) as in 
spleen (compare Figure S3A and Figure S3B), ruling 
out the hypothesis of higher T-cell density in spleen as 
a factor favoring CD4+CD8+ cell differentiation in this 
organ. However, in mLN, CD4+CD8+ cells were 
almost completely segregated from CD4+ and CD8+ 
single-positive cells in Tg8 mice. Specifically, 
CD4+CD8+ cells were clustered in the medullary 
sinuses, whereas single-positive cells occupied the 
regular T-cell areas in the subventricular zones 
(Figure S3B). This finding and the low CD62L and 
CCR7 expression on peripheral CD4+CD8+ cells 
(Figure S2D) strongly suggest that unlike normal T 
cells, CD4+CD8+ cells entered the mLN through the 
afferent lymph rather than through high endothelial 
venules, leading to the spatial segregation of double- 
and single-positive cells. This also confirmed that in 
Tg8 mice, peripheral CD4+CD8+ cells are not 
generated in mLN. 
Lack of positive selection of CD4+CD8+ cells 
generated in spleen 
We hypothesized that CD4+CD8+ cell 
accumulation in spleen was due to a defect in the 
positive selection of new CD4+CD8+ cells generated in 
this organ. One of the early events in the positive 
selection of T cells is CD69 upregulation [13-15]. 
Indeed, around 5% of WT and Tg8 thymic CD4+CD8+ 
cells expressed CD69 (Figure 3A). This CD69+/CD4+ 
CD8+ cell population was strongly reduced in Tg8 





spleens (Figure 3A), suggesting that spleen cannot 
positively select CD4 or CD8 single-positive cells or 
that splenic CD4+CD8+ cells have intrinsic defects that 
arrest them at this stage. To rule out this second 
hypothesis, we performed transfer experiments in 
which we injected allelically marked splenic double- 
and single-positive cells from Tg8 mice in the spleen 
or thymus of recipient Tg8 mice. As expected, CD4+ 
single-positive cells were stable and remained 
single-positive after injection in thymus or spleen 
(Figure 3B “4SP”). Consistent with all our previous 
data, donor CD4+CD8+ cells became single-positive 
cells only after injection in thymus (Figure 3B lower 
panel “DP”), but not after injection in spleen (Figure 
3B top panel “DP”). 
Altogether, our data demonstrate that in Tg8 
mice, extrathymic CD4+CD8+ cells generated in spleen 
do not have intrinsic developmental deficiency; 
however, they are not in the right environment, 
therefore they cannot be positively selected, and 
accumulate in the periphery. Hence, we hypothesized 
that splenic CD4+CD8+ cells could be at the origin of 
T-ALL in our model of DLL4-driven T-ALL. 
Spleen is required for extrathymic CD4+CD8+ 
cell generation and T-ALL development in Tg8 
mice 
First, we wanted to prove that thymus was not 
required for DP cell accumulation at the periphery in 
Tg8 mice. To this aim, we performed thymectomies in 
3-week-old Tg8 mice. In accordance with all data 
presented above, we observed that the fraction of 
extrathymic CD4+CD8+ cells was not affected by 
thymus removal (compared with sham surgery, 
Figure 4A). This formally demonstrates that in Tg8 
mice, peripheral CD4+CD8+ cells are not generated in 
the thymus. All Tg8 mice (surgery and sham surgery) 
developed T-ALL with identical timing (data not 
shown), indicating that extrathymic CD4+CD8+ cells 
might be needed for T-ALL development. 
Then, to determine the role of spleen in Tg8 
mice, we splenectomized 3-week-old Tg8 mice. 
Circulating CD4+CD8+ cells were below detection 
level in splenectomized mice, while they accumulated 
normally in sham-operated Tg8 mice (Figure 4B). 
Neither CD4+CD8+ cell development in thymus 
(Figure S4A) nor DLL4 expression in peripheral Tg8 T 
cells was affected by splenectomy (Figure S4B). 
Therefore, we concluded that the spleen is required 
for extrathymic development in the Tg8 mouse model 
of DLL4-driven T-ALL. Strikingly, even one month 
after all sham-operated mice had died due to T-ALL, 
splenectomized Tg8 mice were fully protected against 
leukemia development (Figure 4C). These data 
indicate that extrathymic CD4+CD8+ cells are at the 
origin of T-ALL in Tg8 mice. 
To demonstrate that spleen is specifically 
required for DLL4-driven T-ALL development, we 
used a Notch Intracellular Domain (NICD)-driven 
T-ALL mouse model (i.e. EF1a-N1IC R26-Cre ER 
mice) in which Notch1 NICD is preceded by 
Flox/STOP/Flox [16]. We transplanted BM from 
EF1a-N1IC R26-Cre ER mice in lethally irradiated 
mice, and after 4 weeks, we splenectomized or 
sham-operated these mice. Upon induction of NICD 
expression by treatment with tamoxifen at week 2 
post-surgery, all splenectomized and sham-operated 
mice succumbed to T-ALL at the same time (data not 
shown), indicating that spleen is not required for 
T-ALL development when Notch can be activated in 
the absence of DLL4. At early stages (i.e. at week 2 
after NICD induction), we started to detect CD4+CD8+ 
cells in peripheral blood from sham-operated mice 
and also, but to a lower extent, in splenectomized 
mice (Figure S4C). This suggested that spleen is a 
preferential location for extrathymic CD4+CD8+ cell 
development even upon NICD expression. 
Altogether, our results demonstrate that splenic 
extrathymic T-cell development is at the origin of 
T-ALL in the DLL4-driven T-ALL Tg8 mouse model. 
In DLL4-expressing T-ALL, demcizumab has 
the same therapeutic effect as γ-secretase 
inhibition 
To assess the clinical significance of our findings 
in Tg8 mice, we first analyzed DLL4 mRNA 
expression in a publicly available database of human 
T-ALL specimens [17] after transforming the TPM 
values for DLL4 expression into Z-scores. We found 
that 2.6% of these samples had a Z-score > 2 (in red in 
Figure 5A). Pairwise Pearson correlation analysis of 
TPM values did not highlight any significant 
correlation between DLL4 expression and other 
members of the Notch signaling pathway (NOTCH1, 
NOTCH3, HES1, DTX1 and MYC) (Figure S5). 
Moreover, unsupervised hierarchical clustering of the 
samples from this dataset revealed that four of the 
seven samples with the highest DLL4 expression 
(Z-score > 2) clustered together (Figure S6). Finally, a 
completely unsupervised approach to identify 
mutations enriched in those seven T-ALL samples 
with the highest DLL4 mRNA expression did not 
identify any significant association with any 
mutation. Still, in five of the seven T-ALL samples 
mentioned above, we found NOTCH1 somatic 
mutations, but the available data did not allow us to 
determine the heterozygosity frequency in this subset 
compared with the DLL4-negative samples. 






Figure 2. All early T-cell developmental stages are found in the spleen of Tg8 mice. A) Spleen, bone marrow (BM) and liver tissues from 7-week-old Tg8 animals 
were homogenized and stained. DN cells were negatively gated on lineage (Lin = CD3/4/8/19/11c/F4/80/Gr1/FcεRI/TCRγδ), positively gated on Thy1.2+, and classified as 
DN1-DN4 with anti-CD25 and -CD44 antibodies. Data are representative of n = 4 mice for each genotype. B) DN1/DN2/DN3/DN4 cells from spleen of Tg8 mice identified as 
in (A) were stained with antibodies against pre-TCRα (pTα). Representative data from n = 4 mice. C) Spleen and bone marrow cells from 3-week-old Tg8 and WT animals were 
homogenized and stained. LSK cells were negatively gated on lineage (Lin = CD3/4/8/19/11c/F4/80/Gr1/FcεRI/TCRγδ), positively gated on cKit expression, and then analyzed for 
Sca1 expression. Data are representative of n=4 mice for each genotype. CD4+CD8+ cells D) and progenitor LSK cells E) are found at the bridging channels (BC) of the marginal 
sinus endothelia surrounding the peri-arteriolar lymphoid sheaths. Frozen spleen sections from 14-day-old Tg8 and WT mice were fixed and stained with anti-CD4, anti-CD8, 
anti-MADCAM, anti-c-Kit, anti-FcεRI and secondary antibodies conjugated with fluorescent dyes. Arrows indicate BCs, which are the discontinuities of the marginal sinus 
endothelia stained with MADCAM in both (D) and (E). Arrowheads indicate CD4+CD8+ (D) and LSK cells (E). Data are representative of n = 5 mice per genotype. 






Figure 3. Lack of positive selection of CD4+CD8+ splenic Tg8 cells. A) Spleen, and thymus tissues from 7-week-old Tg8 animals were homogenized and stained. Cells 
were gated for CD3 expression, and CD3+ cells analyzed for CD4, CD8 and CD69 expression. The y-axis shows the percentage of CD69+ cells among all double-positive (DP) 
CD4+CD8+ cells. Data are the mean ± SEM (n = 5 mice per genotype). B) Splenic CD4 single-positive (4SP) cells from Tg8 Thy1.1 animals and CD4+CD8+ (DP) cells from 
7-week-old Tg8 Thy1.1/1.2 animals were sorted separately and co-injected in spleen (top panels) or thymus (bottom panels) of Tg8 Thy1.2 recipient animals. One week later, cells 
were collected from the spleen or thymus of recipient mice, and stained with anti-CD4, -CD8, -Thy1.1 and -Thy1.2 antibodies, cells were positively gated in Thy1.1 for donor cells 
or gated Thy1.2 host cells, and analyzed for CD4 and CD8. Data are representative of n = 5 mice per group. ** p < 0.01 (Mann-Whitney test). 
 
In summary, we conclude that a small subset of 
T-ALL samples displays high DLL4 expression levels 
compared with the other specimens of this dataset 
[17]. However, we could not determine whether in 
these samples DLL4 was expressed at the cell 
membrane of malignant cells or in other cell types 
(e.g. stromal cells). 
Therefore, to evaluate whether in human T-ALL, 
DLL4 is expressed at the cell membrane, we analyzed 
DLL4 protein expression in a small group of already 
available patient-derived T-ALL (PDTALL) models: 
PDTALL 8, 9, 13 and 19. Some of these PDTALLs 
harbor mutations in NOTCH1 (8 and 19) and FBXW7 
(19), whereas the others carry WT NOTCH1 (9 and 13) 
and FBXW7 (8, 9 and 13) [18]. We injected PDTALL 
cells in immunodeficient NRG mice and after 3 weeks, 
we isolated cells from enlarged spleens and analyzed 
DLL4 expression by western blotting. DLL4 
expression was high only in PDTALL13 (Figure 5B). 
Then, we analyzed by flow cytometry DLL4 
expression in PDTALL13 cells and in PDTALL9 and 
19 cells, as negative controls. We found that DLL4 was 
expressed at the membrane in 28% of PDTALL13 cells 
(gated with an anti-human CD45 antibody, Figure 
5C). Conversely, we did not detect any DLL4 
expression in PDTALL9 and 19 cells (Figure 5C). 






Figure 4. Spleen is required for extrathymic CD4+CD8+ cell development in DLL4-driven T-ALL. A) Three-week-old Tg8 mice underwent thymectomy (thyX) or 
sham surgery (mock) and blood cells were collected and stained for CD3, CD4 and CD8 every week after surgery. Cells were gated on CD3 expression, and analyzed for CD4 
and CD8 expression. The left panel shows a representative analysis at week 3 after surgery. The right panel shows the CD4+CD8+/CD4+ (DP/4SP) ratio increase after surgery 
(n = 6 mice per treatment). B) Three-week-old pre-tumoral Tg8 mice underwent splenectomy (splX) or sham surgery (mock). One month after surgery, mice were sacrificed 
and CD4+CD8+ cell accumulation in mesenteric lymph nodes (mLN), bone marrow (BM), liver, and spleen of Tg8 mice determined by flow cytometry (data are representative 
of n=4 mice for each indicated time point). Cells were positively gated using CD3 and analyzed for the expression of CD4 and CD8. Data are representative of n = 4 mice per 
treatment. C) Survival curves of mice that underwent splenectomy (splX) or sham surgery (sham) at 3 weeks of age. n = 12 mice per treatment coming from 2 different 
experiments with 5 and 7 mice per group, respectively. In the first experiment, splenectomized mice were killed when the last sham-operated mouse died of T-ALL and they 
appear as censored (with a tick mark). In the second experiment, splenectomized mice were kept alive for another month after the last sham-operated mouse died, and also 
appear as censored (with a tick mark). Kaplan-Meier survival curves were analyzed with the Gehan-Breslow-Wilcoxon test (p = 0.000012). **** p < 0.0001. 
 
It was previously shown that inhibition of 
murine DLL4 expressed by stroma cells hampers the 
Notch pathway and the viability of some PDTALL 
models in vivo [4]. However, to the best of our 
knowledge, this is the first time that DLL4 expression 
was detected in T-ALL cells. Therefore, we wanted to 
determine whether human DLL4 is required for 
Notch pathway activity and survival of PDTALL13 
cells. To this aim, we incubated PDTALL13 cells in 
vitro with vehicle, demcizumab (a blocking 
anti-human DLL4 antibody), a murine anti-DLL4 
antibody (negative control), or the potent γ-secretase 
inhibitor DBZ, a pan-Notch inhibitor (positive 
control). We used PDTALL9 and 19 cells as negative 
controls for demcizumab treatment. The expression 
levels of DTX1 and HES1 were not significantly 
different in cells incubated with the mouse anti-DLL4 
antibody or vehicle in all tested PDTALL models. 
Conversely, DBZ led to a reduction of HES1 and 
DTX1 expression levels in all tested PDTALL models. 
Moreover, demcizumab efficiently decreased HES1 
and DTX1 levels in PDTALL13 cells, but showed no 
effect in PDTALL9 and 19 cells (Figure 5D). This 
confirmed that the DLL4 detected at the membrane of 
PDTALL13 cells is of human origin, and indicated 
that the Notch pathway is activated by DLL4 in 
PDTALL13 cells. Analysis of cell survival showed that 
the murine anti-DLL4 antibody did not cause death of 
human CD45+ cells in the three PDTALL models, not 
even at the highest concentration (80 µg/ml) (Figure 
5E). Conversely, DBZ (positive control for Notch 
inhibition) promoted cell death in all three PDTALL 
models, but with different kinetics. Demcizumab 
promoted cell death only in PDTALL13 cells, and very 
efficiently. Indeed, we observed a cell death increase 
(compared to vehicle) with only 1 µg/ml. All these 
data confirmed the specificity of demcizumab 
towards T-ALL cells that overexpress DLL4 (Figure 
5C). Moreover, as the Notch pathway provides 
pro-survival signals to T-ALL cells grown in vitro [4, 
19], our cell death data further suggested that 
inhibiting DLL4 signaling in PDTALL13 cells 
abolishes Notch signaling. Finally, we also observed 
that the murine anti-DLL4 antibody caused cell death 
in murine cells (i.e. cells negative for human CD45), 
but only at high concentration (40-80 µg/ml). 





Conversely, demcizumab (negative control) did not 
promote cell death in murine cells, and DBZ (positive 
control) showed a similar murine cell death profile in 
all three PDTALL models (Figure S7). 
 
 
Figure 5. In DLL4-expressing T-ALL, demcizumab treatment showed the same therapeutic effect as γ-secretase inhibition. A) Normalized TPM expression 
levels of DLL4 in 264 T-ALL patient samples (Mullighan dataset) in decreasing order. Samples with the highest expression level (z score > 2) are highlighted in red (top 2.6%). The 
dashed blue horizontal line indicates the mean expression level, and the solid blue horizontal line indicates the median expression level across all samples. B) Analysis of DLL4 
expression by western blotting in four different patient-derived T-ALL (PDTALL). C) The spleens of moribund NRG mice harboring different PDTALL cells were homogenized 
and stained. Cells were gated negatively (DAPI) and positively for CD45 expression, and analyzed for the expression of human DLL4 or the isotype IgG control. PDTALLs were 
expanded in mice before performing the in vitro assays presented in (D), (E) and (F). D) Analysis of HES1 and DTX1 mRNA expression in the indicated PDTALL cells incubated 
with vehicle (control), 20 µg/ml of murine anti-DLL4 antibody, 20 µg/ml of human anti-DLL4 antibody (demcizumab), or 500 nM of DBZ for 48 h. Data (treatments vs control) 
were compared by one-way ANOVA for each PDTALL, n = 3 each condition. E) Viability of PDTALL9 (upper), 13 (middle) and 19 (low) cells incubated with the indicated doses 





of murine anti-DLL4 antibody, human anti-DLL4 antibody (demcizumab), or DBZ for 1, 2 and 3 days. Cells were gated using a human anti-CD45 antibody, and cell death analyzed 
by DAPI staining. Data (treatments vs control) were compared by two-way ANOVA for each day; n = 2 per condition. F) Apoptosis analyses of PDTALL9 (upper), 13 (middle) 
and 19 cells (lower) performed by flow cytometry after staining with AnnexinV and DAPI following incubation with vehicle (control), murine anti-DLL4 antibody, human 
anti-DLL4 antibody, or DBZ as in (D). Data (treatments vs control) were compared by two-way ANOVA, n = 3 per condition. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 
0.0001. 
 
Figure 6. Therapeutic effect of demcizumab in mice harboring DLL4-expressing T-ALL cells. A) PDTALL13 cells were injected IV in NRG mice that were then 
treated with vehicle (IgG, n = 8), DBZ (n = 8), murine anti-DLL4 (n = 8), or human anti-DLL4 antibodies (demcizumab, n = 8). The Y-axis shows the percentage of alive animals 
and the X-axis the days after treatment. Data were compared with the Gehan–Breslow–Wilcoxon test: vehicle vs DBZ (p = 0.02), vehicle vs demcizumab (p = 0.006), murine 
anti-DLL4 antibody vs DBZ (p = 0.0003), and murine anti-DLL4 antibody vs demcizumab (p = 0. 0002). The other comparisons were not significant. Asterisks in the figure are 
for the comparison with the vehicle group. B) Protein expression of the indicated proteins by western blotting of whole cell extracts from spleens of NRG mice treated as in (A). 
C) Formalin fixed-paraffin embedded spleen sections from NRG mice treated as in (A) were stained with anti-HES1 antibodies, DAPI and secondary antibodies conjugated with 
fluorescent dyes. Four random photographs at 20X magnification were taken for each condition and the number of HES1high cells (left) and HES1low cells (right) is presented 
below. Statistical analyses (treatment vs control) were performed by one-way ANOVA for each PDTALL line. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
 
To better investigate cell death in our 
experimental setting, we quantified Annexin V/DAPI 
staining by flow cytometry in the three PDTALL 
models after incubation with DBZ or antibodies 
against murine and human DLL4. Incubation with 
DBZ increased the percentage of Annexin V-positive 
cells (i.e. early apoptosis) in the three PDTALL models 
(Figure 5F), confirming the known role of the Notch 
pathway in T-ALL survival [4, 19]. Moreover, in 
PDTALL13 cells, the percentage of cells in early 
apoptosis was similarly increased after incubation 
with demcizumab. This confirmed that the Notch 
pathway is dependent on DLL4 signaling in this 
model (Figure 5F and Figure S8). 
To determine whether these findings could be 
translated to the clinic, we injected PDTALL13 cells in 
irradiated NRG mice and, 24 h later, we randomized 
mice in four treatment groups: control (vehicle), DBZ, 
murine anti-DLL4 antibody, and demcizumab. In 
accordance with our in vitro data, the median survival 
of mice treated with vehicle (control) or the mouse 
anti-DLL4-antibody was not significantly different (26 
and 24.5 days, respectively) (Figure 6A). Conversely, 
survival was similarly increased in mice treated with 





DBZ or demcizumab (28.5 and 29.5 days respectively) 
compared with the two previous groups (Figure 6A). 
To test whether the different treatments reached their 
targets, we analyzed by western blotting spleen 
samples from mice harboring PDTALL13 cells and 
treated with vehicle, murine or human anti-DLL4, or 
DBZ. The expression levels of Notch intracytoplasmic 
domain (N1ICD) and HES1 were decreased in 
samples from mice treated with demcizumab and 
DBZ compared with mice treated with the murine 
anti-DLL4 antibody or vehicle (Figure 6B). These data 
further demonstrated that DLL4 signaling is the main 
source of Notch activity in PDTALL13. Finally, and to 
demonstrate that the murine anti-DLL4 antibody also 
reached its target, we analyzed HES1 expression by 
immunofluorescence in spleen cells after treatments. 
First, we observed two cell types: one with high HES1 
expression (few cells), and one with low HES1 
expression (many cells) (Figure 6C). DBZ treatment 
decreased both HES1 expression patterns. 
Conversely, the mouse anti-DLL4 antibody decreased 
only the number of HES1high cells, whereas 
demcizumab treatment decreased only the number of 
HES1low cells. These findings strongly suggested that 
HES1high cells are murine and HES1low cells are human 
T-ALL cells. To prove this, we co-stained cells with an 
antibody against human vimentin, an antibody 
against human and murine vimentin, an anti-HES1 
antibody, and DAPI. HES1high cells were only stained 
with the vimentin antibody against murine and 
human cells (Figure S9). Conversely, the abundant 
HES1low cells were stained by both anti-vimentin 
antibodies. This confirmed that HES1high cells are 
murine and HES1low cells are human, even more, also 
that murine anti-DLL4 antibody worked in our 
experimental setting. 
Taken together, our data show that DLL4 is 
strongly expressed in a small subset of T-ALL and 
that inhibition of human DLL4 signaling in a 
DLL4-positive PDTALL inhibits the Notch pathway 
and reduces T-ALL cell survival, as observed upon 
γ-secretase inhibition. All the human data validated 
our findings in our preclinical model of DLL4-driven 
T-ALL and broaden our knowledge on this disease. 
Discussion 
In this work we demonstrated that spleen is 
crucial in DLL4-driven T-ALL. We think that this 
might be explained by a combination of factors, 
particularly the fact that HSCs and T cells are closer in 
spleen than in other peripheral lymphoid organs, and 
the presence of a specific microenvironment 
(cytokines, cell-cell interactions) in spleen. A previous 
study in which murine NICD-driven T-ALL cells 
were injected in nude mice showed that the spleen has 
a role in T-ALL cell colonization. Indeed, 
splenectomized mice survived longer than 
sham-operated control mice, although all mice 
ultimately died [20]. Here, we found that spleen does 
not play a role, or only a limited one, in NICD-driven 
T-ALL because splenectomy did not protect against 
T-ALL development. Conversely, DLL4-driven 
T-ALL development was inhibited by splenectomy, 
demonstrating differences between these models of 
Notch-induced T-ALL. Currently, we cannot rule out 
that besides the extrathymic T-cell development we 
reported here, in Tg8 mice spleen could provide the 
perfect environment for T-ALL precursor survival. 
Our data also highlight the importance of the tight 
temporal and spatial regulation needed for T-cell 
development because the lack of DLL4-driven splenic 
cell positive selection allowed them to survive. 
Moreover, as these cells express DLL4 at the 
membrane, they also generate more CD4+CD8+ cells 
that accumulate until the appearance of additional 
mutations required for T-ALL [6]. The crucial role of 
spleen in our DLL4-driven T-ALL model was 
strengthened by the finding that mice in which spleen 
was surgically removed were in good health even one 
month after the last sham-operated mouse died due to 
T-ALL. However, we cannot rule out that at later 
stages, they could develop the disease. 
 The percentage of T-ALL patients with elevated 
Notch pathway activity is higher than that of patients 
with somatic mutations in NOTCH1 and/or FBWX7, 
suggesting that other mechanisms might support 
NOTCH hyperactivation in T-ALL [21, 22]. For 
instance, increased NOTCH1 levels induce T-ALL in 
Ccnc-/- mice [23], and ectopic DLL4 expression 
promotes T-ALL in mice [6, 7]. Although CCNC loss 
of function mutations have been reported in some 
patients with T-ALL [23], the involvement of 
membrane-bound DLL4 in cancer cells remained 
elusive until our present proof of concept study 
showing DLL4 involvement in the human disease. 
Interestingly, DLL4-expressing PDTALL13 cells do 
not harbor any NOTCH1 or FBWX7 mutation [18]. 
However, we could not find any correlation between 
T-ALL samples with higher DLL4 expression and 
NOTCH1 or FBWX7 mutational status in the T-ALL 
specimens analyzed in Figure 5A [17]. Therefore, 
more work is needed to clarify the relationship 
between DLL4 expression and Notch pathway 
mutations in T-ALL. Finally, our work fits with a 
previous study showing that JAGGED1, another 
Notch ligand, also plays a role in T-ALL [24]. 
Previous work demonstrated that in nude mice 
harboring PDTALL cells, murine anti-DLL4 
antibodies hamper T-ALL growth [4]; however, to the 
best of our knowledge, this is the first study showing 





that human T-ALL cells can express DLL4 to activate 
the Notch pathway. In our case, inhibition of murine 
DLL4 does not show any effect in mice xenografted 
with human PDTALL13 cells. We think that this 
discrepancy is due to the different experimental 
settings because we analyzed the overall survival, 
whereas in the previous work, Minuzzo et al, assessed 
only DLL4 role in early events, most probably 
associated with T-ALL cell colonization [4]. Moreover, 
Minuzzo et al did not use mice xenografted with 
PDTALL13 cells, and this model might rely more on 
human DLL4 expression, and therefore might not be 
influenced by the antibody against the mouse ligand. 
Interestingly, Minuzzo et al detected DLL4 expression 
in spleen, already suggesting that DLL4 and T-ALL 
cell interaction is privileged in this organ [4]. Notch 
plays a crucial role in PDTALL cell survival in vitro [4, 
19]. Similarly, both DBZ and demcizumab hampered 
PDTALL13 cell survival. Although demcizumab 
treatment strongly increased PDTALL13 cell death, at 
this moment we cannot rule out that Notch inhibition 
might affect also the cell cycle in these cells. Similarly, 
we do not know whether DLL4 drives T-ALL 
development in PDTALL13 or whether it is 
ectopically expressed later, but we clearly 
demonstrated that PDTALL13 cells are addicted to 
DLL4-Notch signaling. 
In summary, we provided the proof of concept 
for the role of ectopic DLL4 expression in human 
T-ALL and also solid data indicating that spleen is 
required for tumor development in a mouse model of 
DLL4-driven T-ALL. 
Materials and Methods 
Mice 
Tg8 and EF1a-N1IC mice were previously 
described [6, 16]. NRG (NOD.Cg-Rag1tm1Mom 
Il2rgtm1Wjl/SzJ JAXTM) mice were purchased from 
Charles River (Margate, Kent, UK). All procedures 
used in this study were approved by the local 
Institutional and Animal Care Use Committee. 
Antibodies and staining 
Thymocytes and splenocytes were 
homogenized, stained and data acquired with a BD 
FACSCalibur or BD LSRII apparatus. Data were 
analyzed with the FloJo software (BD Biosciences). 
The following antibodies were used: anti-CD4 
(clone H129.19, BD bioscience), anti-CD8 (53-6.7, 
Biolegend), anti-DLL4 monoclonal antibody YM152F 
(courtesy of Dr. M. Yan, Genentech; final staining 
concentration: 1 μg/mL), goat F(ab’)2 anti-human 
Ig(gamma)-PE as secondary antibody (Invitrogen, 
H10104), and anti-NOTCH1 (HMN1-12, Biolegend). 
Other antibodies used were against Vβs [Vβ3 (JOVI.1, 
Caltag), 4 (KT4, Caltag), 5.1/5.2 (MR9-4, 
PharMingen), 6 (RR4-7, BD), 7(TR310, Caltag), 8.1/8.2 
(MR5-2, BD), 8.3(1B3.3, PharMingen), 9 (MR10-2, BD), 
12 (KT12, Caltag), 13 (mr12-3, BD) and 14 (14-2, 
PharMingen)], CD44 (1M7, eBioscience), CD25 
(PC61.5, eBioscience), pTa (2F5, BD PharMingen), 
Thy1.2 (53-2.1, ebioscience), F4/80 (BM8, Biolegend), 
CD45 (Biolegend #103128; Clone: 30-F11), EpCam 
(Biolegend #118212; clone: G8.8), Ly51 (ebioscience 
#12-5995-81, clone: FG35.4), Ulex europaeus lectin 
(Vector Labs #FL-1061), CD80 (Biolegend #104721; 
clone: 16-10A1), and MHC class II (ebioscience 
#48-5321-82; clone: M5/114.15.2). For mouse 
immunohistochemistry, the following antibodies 
were used: anti-CD4 Alexa 647 (Biolegend #100531; 
clone: RM4-5), anti-CD8 Alexa 488 (Biolegend 
#100723; clone: 53-6.7), anti-CD4 615 (eBioscience 
#42-0042-80; clone: RM4-5), anti-MADCAM-1 
(Biolegend #120705; clone: MECA-367), anti-c-Kit 
Alexa 488 (Biolegend #105815; clone: 2B8), anti-FcεRI 
(Biolegend #134301; clone: MAR-1), and anti-PNAd 
(Biolegend # 120803; clone: MECA-79). Secondary 
antibodies included: anti-rat IgG594 (Biolegend # 
405410), goat anti-armenian hamster IgG Cy3 (Jackson 
Immunoresearch #127-0650160), goat anti-rat IgM 
Alexa Fluor 594 (Invitrogen #A21213), and goat 
anti-rat IgG Alexa 647 (Invitrogen #A-21247). For 
human cytometry analysis we used antibodies 
against: DLL4, clone MHD4-46, BioLegend #346507; 
CD45 clone HI30, eBioscience; 35-0459-42; and 
IgG-control clone MOPC-21, BioLegend, #400121. 
Ultrasound-guided intrathymic/intrasplenic 
injection 
Four-week-old mice were anesthetized with 4% 
isoflurane (Aerrane, Baxter, Deerfield, IL) in medical 
air and maintained under anesthesia using a 
nose-cone with 1.5% isoflurane. Thymus or spleen 
was visualized with a 30-MHz 707B ultrasound probe 
(Visualsonics, Toronto, Canada), then 20 µl of a 5 
mg/ml sulfo-NHS-biotin solution (Thermo Fisher 
Scientific) was injected in the thymus (10 µl in each 
lobe) using a Hamilton syringe and a 30G needle with 
the aid of a 3D micromanipulator. Similarly, 60-80 µl 
of 5 mg/ml sulfo-NHS-biotin solution was injected in 
the spleen in four spots. 
Splenectomy and thymectomy 
For splenectomy, 3-week-old Tg8 mice were 
anesthetized with 0.6 ml/kg of a cocktail containing 
ketamine (12.5 mg/ml), xylazine (2.5 mg/ml) and 
acepromazine (0.5 mg/ml). An approximately 2.5 
cm-long skin incision and a 1cm-long peritoneal wall 
incision were made using scissors on the left side of 
the body where the spleen lays. The spleen was gently 





pulled out. The artery and the afferent venules were 
tied off with a 4-0 suture. Then, spleen was cut and 
removed. The peritoneal wall and the skin were 
closed and sutured. 
For thymectomy, 3-week-old Tg8 mice were 
similarly anesthetized and placed on a heat pad set at 
37°C. A 1 cm ventral, horizontal skin incision centered 
over the clavicle was made, and the first 2-3 left ribs 
were cut near the sternum. The two thymic lobes were 
located and gently removed using forceps and 
vacuum aspiration. The chest cavity was compressed 
and the sutures were tightened to purge the air from 
the chest and reestablish negative pressure. 
Confocal microscopy 
Tissues were embedded in optimum cutting 
temperature (OCT) compound and frozen at -80°C 
until use. Cryostat sections (8-10 mm-thick) were 
fixed with cold acetone at -20°C for 10 min and 
blocked in PBS with 5% BSA and 10% FCS at room 
temperature for 10 min. Confocal images were 
acquired with a Olympus Fluoview BX50W1 
microscope and a Bio-Rad Radiance confocal system 
with 488-, 568- and 637- nm excitation lines, 560 and 
650 nm detectors and HQ515/30 and HQ600/40 
filters. Images were obtained with a Plan-Apochromat 
20X (NA 0.8) and 60X (NA 1.4) immersion 
oil-objectives. Images were exported to Image J 1.43u 
for processing. 
Human sample analysis 
Public RNA-seq gene expression data was 
obtained for human T-ALL samples [17]. This gene 
expression data set contained FPKM values for 264 
T-ALL samples, which were normalized using 
quantile normalization, and then transformed to 
corresponding TPM values. In order to identify a 
subset of samples with higher expression of DLL4 
relative to the rest of samples, we log-transformed the 
TPM values for DLL4 to compute Z-scores and picked 
the samples that had Z > 2 to find observations that 
exceed the mean by at least 2 standard deviations. In 
order to determine if the samples with Z > 2 for DLL4 
were similar to each other in terms of their gene 
expression profiles, we performed unsupervised 
hierarchical clustering of the samples from this data 
set using Pairwise Pearson Correlation Coefficient as 
the distance metric between the samples. For gene 
expression correlation we performed Pairwise 
Pearson correlation analysis. 
Protein expression in patient-derived T-ALL 
(PDTALL) and in vitro experiments 
PDTALL were already developed before this 
study after informed consent from the patients and 
the approval by the University Medical Center 
Institutional Review Board committee [18]. Spleens 
from NRG mice harboring the different PDTALL 
models were harvested and proteins extracted. 
Western blotting was performed as before [25] with 
anti-DLL4 (C19035, LSBio) and anti-GAPDH (#5174, 
Cell Signaling technologies) primary antibodies. 
PDTALL9, 13 or 19 cells were harvested from the 
spleen of moribund NRG mice, resuspended and 
cultured in DMEM+20% FBS supplemented with 
non-essential amino acids and pyruvate. Cells were 
incubated with vehicle, murine anti-DLL4 (mDLL4), 
human anti-DLL4 (hDLL4) antibodies, or γ-secretase 
inhibitor (DBZ) for 24, 48 and 72 h with different 
concentrations for each treatment. At indicated 
timepoints cell viability was assessed by FACS using 
DAPI (Sigma) and an anti-human CD45 antibody to 
discriminate murine and human cells (clone HI30, 
#35-0459-42 eBioscience). 
For apoptosis assay PDTALLs were expanded in 
mice and cultured as described above. Cells incubated 
with vehicle, murine anti-DLL4 or human anti-DLL4 
(demcizumab) antibodies (both at 20 mg/ml), or 
γ-secretase inhibitor (DBZ, 500 nM) for 48h were 
analyzed by FACS (Cytoflex, Beckman Coulter) using 
an anti-human CD45 antibody (clone HI30, 
#35-0459-42, eBioscience), AnnexinV apoptosis 
detection kit (#556547, BD Pharmigen) and DAPI 
(Sigma). 
Patient-derived T-ALL (PDTALL) in vivo 
experiments 
1×106 PDTALL13 cells were IV injected in 32 
irradiated NRG mice. Mice partial body irradiations 
were performed using a rotational X-ray irradiator 
(Xenx, Xstrahl, Experimental Radiotherapy Core 
Facility, IRCM, Montpellier, France). Single doses of 
4.5 Gy were delivered at a dose rate of 2.7 Gy/min 
(225 kV and 13.6 mA) to the mice under sedation. 
After 1 week, mice were randomized (n = 8 
mice/group) and treated with vehicle or anti-IgG 
control, 20 mg/kg/week of demcizumab (anti-human 
DLL4 antibody, Oncomed, Redwood City, CA, USA), 
20 mg/kg/week of anti-mouse DLL4 antibody 
(Oncomed), or 3.3 mg/kg/day, from Monday to 
Thursday, of dibenzazepine (DBZ) (Synkon, 
Groningen, Netherlands), as previously described 
[26]. 
Spleens of moribund mice treated as above were 
formalin fixed and paraffin-embedded. For 
Immunofluorescence, the following antibodies were 
used: anti-HES1 (clone D6P2U, # 11988, Cell Signaling 
Technology); anti-human vimentine (vimentine (h); 
clone V9, # 790-2917), anti-mouse/human vimentine 
(vimentine (m/h); clone D21H3, #7541, Cell Signaling 
Technology) and DAPI (Sigma). All stainings were 





performed using Discovery Ultra automated system 
(Ventana) at RHEM (Réseau d'Histologie 
Expérimentale de Montpellier). Images were acquired 
using Thunder Imaging System (Leica) microscope. 
For each spleen, 4 random fields (×20 magnification) 
were analyzed using ImageJ software. 
Statistical Analysis 
Unless otherwise specified, data are presented as 
the mean ± SEM. The Mann–Whitney test was used to 
assess the statistical significance of cytometry data. 
The Kaplan-Meier survival curves were analyzed 
with the Gehan–Breslow–Wilcoxon test. No mouse 
was excluded for the survival curves. Samples (cells 
or mice) were allocated to their experimental groups, 
according to their pre-determined type: cell type, 
mouse genotype, or mouse treatment. * p < 0.05; ** p < 
0.01; *** p < 0.001; ****p < 0.0001. 
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